Cadrenal Therapeutics Reports Fourth Quarter 2025 Financial Results; Provides Corporate Update on CAD-1005 Program for HIT Following End-of-Phase 2 FDA Meeting Cadrenal Therapeutics, Inc. (Nasdaq: CVKD),

#CVKD Cadrenal Therapeutics Reports Fourth Quarter 2025 Financial Results; Provides Corporate Update on CAD-1005 Program for HIT Following End-of-Phase 2 FDA Meeting

www.stocktitan.net/news/CVKD/cadrenal-thera...

Cadrenal Therapeutics Highlights Research Supporting 12-LOX Inhibition in Reducing Inflammation in Obesity and Type 2 Diabetes Cadrenal Therapeutics (Nasdaq: CVKD) highlighted research supporting its first-in-class 12-lipoxygenase (12-LOX) inhibitor, CAD-1005, as a potential approach to reduce obesity- and Type 2 diabetes‑related inflammation. Preclinical oral dosing showed improved glycemic control, preserved pancreatic β-cells, fewer inflammatory cells in adipose and pancreas, and lower adipose pro-inflammatory cytokines. Cadrenal acquired the 12-LOX portfolio in December 2025 and reported Phase 2 results showing reduced thrombotic events in suspected HIT. The company is developing next-generation CAD-2000.

#CVKD Cadrenal Therapeutics Highlights Research Supporting 12-LOX Inhibition in Reducing Inflammation in Obesity and Type 2 Diabetes

www.stocktitan.net/news/CVKD/cadrenal-thera...

Cadrenal Therapeutics Highlights Recent 12-LOX Inhibitor Platform Expansion Cadrenal Therapeutics (Nasdaq: CVKD) expanded its pipeline with a portfolio of selective 12-LOX inhibitors, including oral candidates, and reported encouraging blinded Phase 2 data for CAD-1005 in heparin-induced thrombocytopenia (HIT).CAD-1005 showed a reduction in thrombotic events on standard anticoagulants and an End-of-Phase 2 (EOP-2) meeting is scheduled this month (March 2026). Management positions 12-LOX inhibition as a differentiated platform with potential acute and chronic applications across inflammatory and thrombotic diseases.

#CVKD Cadrenal Therapeutics Highlights Recent 12-LOX Inhibitor Platform Expansion

www.stocktitan.net/news/CVKD/cadrenal-thera...

Cadrenal's Pipeline Looks Less Like a Microcap and More Like an Emergency Response System Cadrenal Therapeutics (NASDAQ:CVKD) is positioning its pipeline as a hospital-focused anticoagulation platform on December 30, 2025. The company pairs a Phase 3-ready vitamin K antagonist, tecarfarin, aimed at renal-impaired and dialysis patients, with an acquired Factor XIa inhibitor portfolio for acute hospital care. Cadrenal also holds VLX-1005, a Phase 2 12-LOX inhibitor with Orphan Drug and Fast Track designations for heparin-induced thrombocytopenia (HIT). Together the assets span chronic, acute, and immune-mediated anticoagulation failures, targeting high-acuity hospital needs rather than broad-market incremental gains.

#CVKD Cadrenal's Pipeline Looks Less Like a Microcap and More Like an Emergency Response System

www.stocktitan.net/news/CVKD/cadrenal-s-pip...

Cadrenal Is Rebuilding the Parts of Anticoagulation Everyone Else Gave Up On Cadrenal Therapeutics (NASDAQ:CVKD) is pursuing underserved anticoagulation patients with a three‑pillar pipeline targeting chronic, acute, and immune‑mediated thrombosis.Key elements: a Phase 3‑ready vitamin K antagonist tecarfarin designed for kidney‑impaired and dialysis patients; an acquired Factor XIa inhibitor portfolio for acute hospital care; and VLX‑1005, a Phase 2 12‑LOX inhibitor for heparin‑induced thrombocytopenia with Orphan Drug and Fast Track designations.The company positions this asset mix as a purpose‑built platform to address high‑risk patients where existing anticoagulants perform poorly.

#CVKD Cadrenal Is Rebuilding the Parts of Anticoagulation Everyone Else Gave Up On

www.stocktitan.net/news/CVKD/cadrenal-is-re...

Cadrenal Therapeutics to Conduct Partnering and Investor Meetings During the J.P. Morgan 44th Annual Healthcare Conference in San Francisco on January 12-15, 2026 Cadrenal Therapeutics (Nasdaq: CVKD) said management, including CEO Quang X. Pham, will hold partnering and investor meetings during the J.P. Morgan 44th Annual Healthcare Conference in San Francisco on January 12-15, 2026. The company highlighted two 2025 acquisitions and stated its focus on the $40 billion anticoagulation market.Cadrenal's pipeline items cited: VLX-1005 (phase 2 IV 12-LOX inhibitor; ODD and Fast Track for HIT), tecarfarin (phase 3-ready oral VKA; ODD and Fast Track for ESKD with AFib; ODD for LVAD in collaboration with Abbott), and frunexian (phase 2-ready IV FXIa inhibitor for acute care).

#CVKD Cadrenal Therapeutics to Conduct Partnering and Investor Meetings During the J.P. Morgan 44th Annual Healthcare Conference in San Francisco on January 12-15, 2026

www.stocktitan.net/news/CVKD/cadrenal-thera...

Trade Alerts, Monday December 16, 2025 – Crystal Equity Research

Small-cap stocks gapping down in trading, Tue Dec 16th - #VBIX #SVRE #DXST #CVKD #ZYXI #LWLG #IRBT #DFLI #CLLS #AKTX - More: crystalequityresearch.com/trade-alerts... - #smallcap

Cadrenal's Anticoagulation Platform Is Expanding in a $40 Billion Market Cadrenal Therapeutics (NASDAQ:CVKD) is expanding from a single-asset microcap into a multi‑asset anticoagulation platform addressing a $40 billion market.The company acquired a Factor XIa portfolio for hospital use, bought VLX-1005 (Phase 2) with Orphan Drug and Fast Track designations for heparin‑induced thrombocytopenia, and is advancing tecarfarin toward Phase 3 readiness for difficult‑to‑treat chronic anticoagulation patients.Management says these moves create chronic and acute care reach, multiple mechanistic approaches, and near‑term clinical catalysts that could prompt a market revaluation.

#CVKD Cadrenal's Anticoagulation Platform Is Expanding in a $40 Billion Market

www.stocktitan.net/news/CVKD/cadrenal-s-ant...

Cadrenal Therapeutics Acquires VLX-1005, a First-in-Class Phase 2 12-LOX Inhibitor for Patients with Heparin-Induced Thrombocytopenia (HIT) Cadrenal Therapeutics (NASDAQ: CVKD) announced on Dec 11, 2025 the acquisition of VLX-1005 and related 12-LOX assets from Veralox Therapeutics, adding a late-stage, first-in-class small‑molecule 12‑lipoxygenase inhibitor for heparin‑induced thrombocytopenia (HIT).VLX-1005 has U.S. Orphan Drug and Fast Track designations, completed two Phase 1 studies showing favorable tolerability, and interim Phase 2 data reporting reductions in thromboembolic events. The release cites a $40 billion global anticoagulation market and an estimated $1 billion HIT market in the US and EU. Veralox may receive upfront, milestone payments and royalties upon commercialization.

#CVKD Cadrenal Therapeutics Acquires VLX-1005, a First-in-Class Phase 2 12-LOX Inhibitor for Patients with Heparin-Induced Thrombocytopenia (HIT)

www.stocktitan.net/news/CVKD/cadrenal-thera...

Cadrenal Therapeutics CEO, Quang X. Pham, Receives BioFlorida’s Executive of the Year Award Agilent Technologies (NYSE: A) announced the Altura Ultra Inert HPLC columns, a new product line aimed at biotherapeutics analysis including peptide GLP-1 and oligonucleotide workflows. The release highlights faster conditioning, improved peak shape, enhanced sensitivity, and a fully inert sample flow path designed for demanding QC and development labs.Agilent claims up to 2x sensitivity, 3x signal-to-noise ratio, and, when paired with the Agilent 1290 Infinity III Bio LC, up to 30x higher peak area; an external test cited a ~30% sensitivity increase and reduced peak tailing on acidic peptides.

#CVKD Cadrenal Therapeutics CEO, Quang X. Pham, Receives BioFlorida’s Executive of the Year Award

www.stocktitan.net/news/CVKD/cadrenal-thera...

Cadrenal Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update Cadrenal Therapeutics (Nasdaq: CVKD) reported Q3 2025 results and clinical and corporate updates on November 10, 2025. Key development milestones include cGMP manufacturing completion for tecarfarin, ongoing activities supporting a single-site U.S. Phase 2 tecarfarin study in LVAD patients with Abbott, and investigator discussions for a potential multi-site Phase 2 dialysis study.In September 2025 Cadrenal acquired eXIthera assets, adding a Phase 2-ready IV Factor XIa inhibitor, frunexian, aimed at acute care and device-related thrombosis settings. Q3 financials: R&D $0.7M, G&A $2.0M, net loss $2.7M, cash and equivalents $3.9M, and ~2.1M shares outstanding.

#CVKD Cadrenal Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

www.stocktitan.net/news/CVKD/cadrenal-thera...

#CVKD: Acquires Factor XIa Inhibitors… buff.ly/AdCrzWL

$38B Anticoagulation Market Shake-up: Cadrenal Acquires First-in-Class Factor XIa Pipeline from eXIthera Biotech firm gains Phase 2-ready IV drug frunexian and oral EP-7327 for thrombosis treatment. Deal includes $15M in milestones plus royalties, targeting $38B global market.

#CVKD Cadrenal Therapeutics Enhances Anticoagulation Pipeline Through Acquisition of eXIthera’s Portfolio of Factor XIa Inhibitors

www.stocktitan.net/news/CVKD/cadrenal-thera...

Cadrenal Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update Cadrenal Therapeutics (NASDAQ:CVKD) has reported its Q2 2025 financial results and announced strategic plans for tecarfarin clinical trials. The company will initiate trials for patients with End-Stage Kidney Disease (ESKD) transitioning to dialysis, leveraging tecarfarin's orphan drug and fast-track designations.Key financial metrics include R&D expenses of $1.1M (down from $1.3M in Q2 2024), G&A expenses of $2.7M (up from $1.2M), and a net loss of $3.7M (increased from $2.4M). Cash position stands at $5.6M as of June 30, 2025.Operational highlights include successful technical transfer of tecarfarin manufacturing to a U.S. CDMO site, completion of clinical drug product manufacturing, and inclusion in Russell indexes. The company continues exploring development partnerships while focusing on addressing critical anticoagulation therapy gaps.

#CVKD Cadrenal Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

www.stocktitan.net/news/CVKD/cadrenal-thera...

First-Ever Clinical Trial Targets Life-Threatening Gap in Kidney Disease Patient Care During Dialysis Transition Novel anticoagulant with FDA fast-track status aims to reduce mortality risk in ESKD patients transitioning to dialysis. First study of its kind. See trial details.

#CVKD Cadrenal Therapeutics Announces Clinical Trial Initiation Plans for Tecarfarin in Patients with End-Stage Kidney Disease (ESKD) Transitioning to Dialysis

www.stocktitan.net/news/CVKD/cadrenal-thera...

New Research Reveals Shocking $54K Cost Per LVAD Patient Bleeding Event - This Drug Could Be the Solution New study reveals massive healthcare costs for LVAD patients on anticoagulation. See how Cadrenal's tecarfarin could revolutionize treatment for this high-risk group. Learn more.

#CVKD Cadrenal Therapeutics Highlights New Research on Anticoagulation Burden for LVAD Patients

www.stocktitan.net/news/CVKD/cadrenal-thera...

Cadrenal Therapeutics Eyes Strategic Partnerships at World's Largest Biotech Convention Cadrenal executives to discuss tecarfarin development and partnership opportunities at BIO 2025. Schedule your one-on-one meeting to explore collaboration potential.

#CVKD Cadrenal Therapeutics to Engage Potential Partners at BIO International Convention 2025

www.stocktitan.net/news/CVKD/cadrenal-thera...

#CVKD: Preparations Continue for Phase 3 Trial of Tecarfarin… buff.ly/S6w3l9K

Cadrenal Therapeutics Announces Tecarfarin Manufacturing Progress in Support of Clinical Trial Readiness Cadrenal Therapeutics (NASDAQ: CVKD) has achieved key manufacturing milestones for tecarfarin, its lead drug candidate. The company successfully completed the technical transfer and manufacturing of tecarfarin drug substance under cGMP standards at a U.S.-based CDMO facility earlier this year. The manufacturing of the drug product candidate is currently in progress.Tecarfarin is a novel oral vitamin K antagonist (VKA) anticoagulant designed to address unmet needs in anticoagulation therapy for patients with cardiovascular disease. The manufacturing progress represents a significant step in supporting the company's clinical development strategy.

#CVKD Cadrenal Therapeutics Announces Tecarfarin Manufacturing Progress in Support of Clinical Trial Readiness

www.stocktitan.net/news/CVKD/cadrenal-thera...

Cadrenal Therapeutics Reports First-Quarter 2025 Financial Results and Provides Corporate Update Cadrenal Therapeutics (NASDAQ: CVKD) reported its Q1 2025 financial results and corporate updates. Key highlights include: appointment of Dr. James Ferguson as Chief Medical Officer, a successful FDA Type D Meeting providing guidance for tecarfarin's Phase 3 trial, and a Collaboration Agreement with Abbott for the TECH-LVAD trial. The company completed technical transfer of tecarfarin manufacturing to a U.S. CDMO and conducted market research showing growth potential in the LVAD market. Financial results show R&D expenses of $1.7M (up from $0.6M in Q1 2024), G&A expenses of $2.3M (up from $1.1M), and a net loss of $3.8M. Cash position stands at $7.3M as of March 31, 2025, down from $10.0M at year-end 2024.

#CVKD #ABT Cadrenal Therapeutics Reports First-Quarter 2025 Financial Results and Provides Corporate Update

www.stocktitan.net/news/CVKD/cadrenal-thera...

Cadrenal Takes Center Stage: Key Executives to Showcase Novel Anticoagulant at Industry-Leading Events Senior executives to present Phase 3-ready anticoagulant tecarfarin at major industry conferences, engaging with experts and potential partners. Full schedule inside.

#CVKD Cadrenal Therapeutics Participates in Key Medical and Business Development Conferences

www.stocktitan.net/news/CVKD/cadrenal-thera...

#CVKD: Preparing for Phase 3 Trial of Tecarfarin… buff.ly/ipkMS5b

Cadrenal Secures FDA Orphan Drug Status and Abbott Partnership for Breakthrough Phase 3 Trial Cadrenal advances tecarfarin development with Abbott collaboration and FDA Orphan Drug designation, while reporting $10.7M net loss and strong $10M cash position for Phase 3 trial.

#CVKD #ABT Cadrenal Therapeutics Reports Full Year 2024 Results, Business Highlights, and Path Forward for Clinical Advancement of Tecarfarin

www.stocktitan.net/news/CVKD/cadrenal-thera...

#CVKD: Collaborating with Abbott for Pivotal Phase 3 Trial… buff.ly/6K7FZXX

Can Cadrenal's Tecarfarin Revolutionize Treatment for HeartMate 3 LVAD Patients? Abbott to provide expertise and support for Cadrenal's TECH-LVAD study evaluating tecarfarin in heart failure patients, targeting a $1.1B market with projected growth.

#CVKD #ABT Cadrenal Therapeutics Announces Collaboration Agreement with Abbott in Support of Pivotal Study of Tecarfarin in Patients with HeartMate 3™ LVAD

www.stocktitan.net/news/CVKD/cadrenal-thera...

Former Amgen & AstraZeneca Executive Takes Helm of Revolutionary Anticoagulation Drug Development Cadrenal Therapeutics appoints James Ferguson, MD, as CMO to lead tecarfarin development, bringing 25+ years of cardiovascular expertise from Amgen and AstraZeneca to advance groundbreaking therapy.

#CVKD Cadrenal Therapeutics Announces Chief Medical Officer Transition to Advance Clinical Development of Tecarfarin

www.stocktitan.net/news/CVKD/cadrenal-thera...

Cadrenal Therapeutics Advances Tecarfarin Development with FDA Orphan Drug Status and $11.3M Cash Position Cadrenal secures Orphan Drug Designation for tecarfarin in LVAD patients, completes manufacturing prep for Phase 3 trial, and strengthens financial position for 2024.

#CVKD Cadrenal Therapeutics Provides 2024 Year-End Company Update, Reinforcing Clinical Development Plan for Tecarfarin in LVAD and Other Rare Cardiovascular Indications

www.stocktitan.net/news/CVKD/cadrenal-thera...

JUST IN: ( NASDAQ: #CVKD ) Cadrenal Therapeutics Gears Up for the 43rd Annual J.P. Morgan Healthcare Conference Week with Event Participation and Investor/Partner Meetings

#StockMarket #News

Cadrenal Therapeutics to Showcase Novel Anticoagulant Tecarfarin at J.P. Morgan Healthcare Conference Cadrenal CEO to present Phase 3 plans for tecarfarin, a breakthrough treatment for warfarin-dependent cardiac patients, at three major healthcare events in January 2024.

#CVKD Cadrenal Therapeutics Gears Up for the 43rd Annual J.P. Morgan Healthcare Conference Week with Event Participation and Investor/Partner Meetings

www.stocktitan.net/news/CVKD/cadrenal-thera...

NEWS: ( NASDAQ: #CVKD ) Learn to Evaluate (CVKD) using the Charts

#StockMarket #News